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-Re: Randomized Trial of
High-Dose Chemotherapy and
Blood Cell Autografts for
High-Risk Primary Breast
Carcinoma
In the February 2 issue of the Journal,
Hortobagyi et al. (1) reported on a ran-
domized trial of high-dose chemo-
therapy (HDCT) and stem-cell support
versus conventional chemotherapy in
high-risk patients with breast cancer,
who showed no clinically or statistically
significant difference in relapse-free or
overall survival. This trial was based on
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previous phase II studies (2) that
showed a substantial advantage for pa-
tients treated with HDCT in comparison
with historical control subjects. The au-
thors enrolled only 78 patients because
they expected a overly optimistic 3-year
difference of 30% between the two
groups. The present study and other re-
cent reports (3) clearly show that im-
provements, if any, of HDCT on the out-
come of high-risk patients with breast
cancer are likely to be slight. For this
reason, all the clinicians working in this
field, including the authors of the paper,
agree that the results of large random-
ized trials (which have now completed
their accrual) must be awaited to finally
understand the role of the HDCT ap-
proach in the treatment of breast cancer.
This attitude is even more necessary in
view of the reported serious irregulari-
ties in the only randomized study show-
ing a statistically significant survival ad-
vantage for this type of approach as
adjuvant therapy for high-risk patients (4).
In addition, we believe that major
medical journals should consider the
policy of not publishing small, albeit
randomized, studies that at this point,
are likely to add little clinical informa-
tion to this issue.
It has been reported that HDCT with
stem-cell transplantation is more effec-
tive in patients with advanced breast
cancer who respond to conventional
treatment (5). Furthermore, lymph node
status and the degree of tumor remission
after primary chemotherapy in patients
with operable breast cancer represent
the most important prognostic factors
for relapse-free survival (6).
Similar to stage IV disease, the ben-
efits of HDCT intensification in patients
with stage II or III disease may well be
modest in those who respond poorly to
primary chemotherapy. Zambelli et al.
(7) have recently reported discouraging
results with HDCT in high-risk (10
lymph nodes involved at surgery) pa-
tients with breast cancer whose tumors
respond poorly to neoadjuvant anthracy-
cline-containing regimens.
In the study by Hortobagyi et al. (1),
randomization included 30 patients with
axillary lymph node involvement after
four cycles of preoperative chemo-
therapy, but the authors did not specify
whether tumor response was a criterion
for accrual. Moreover, the authors do
not appear to consider additional prog-
nostic factors, including c-erbB-2 status
and proliferative capacity. Given the
small number of patients studied, these
drawbacks might have hampered the
evaluation of clinical results.
Finally, in the study by Hortobagyi et
al., patients in the HDCT arm were
given two cycles of high-dose, nonmyelo-
ablative chemotherapy with stem-cell
rescue. In contrast, the uncontrolled
studies of HDCT that showed a survival
advantage in patients with breast cancer
(2) relied on single, more intensive, and
possibly more active regimens.
PAOLO PEDRAZZOLI
ANDREA SARTORE BIANCHI
MONICA RENGA
SALVATORE SIENA
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EDITOR’S NOTE
Like other journals, we give particu-
larly high priority to definitive clinical
studies, whether positive or negative.
Small studies often have wide confi-
dence intervals associated with treat-
ment effects and are more subject to
random error than are large studies.
Therefore, small studies can fail to de-
tect small treatment benefits. On the
other hand, they are also more subject to
falsely positive results. However, when
the procedure itself (i.e., bone marrow
transplantation) carries a high risk of
morbidity and finite risk of mortality,
the potential magnitude of benefits
should be accordingly large. In such
cases, even small studies can supply im-
portant information in guiding clinical
practice.
Additionally, no study exists in a
vacuum. In the last year, there have been
several studies on high-dose chemo-
therapy, bone marrow transplantation,
and high-risk primary breast cancer—
one positive (1) [that has been discred-
ited (2)] and four negative (3–6). The
results of the negative studies can be
used in aggregate to help determine if a
benefit of sufficient magnitude exists to
fully counterbalance the substantial tox-
icity incurred by high-dose chemo-
therapy and bone marrow or stem-cell
“rescue.” The jury is still out on the ul-
timate role of high-dose chemotherapy
in operable breast cancer. However, the
results of randomized trials such as
those conducted by Hortobagyi et al. do
suggest that the substantial number of
published uncontrolled studies gave an
overly optimistic impression of the
therapy’s strategic worth.
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RESPONSE
The letter by Pedrazzoli et al. en-
dorses the conclusions of our random-
ized, high-dose chemotherapy trial for
high-risk primary breast cancer. It also
underlines our plea that definitive con-
clusions about the efficacy of high-dose
chemotherapy be reserved until the ma-
ture results of large randomized trials
become available.
Furthermore, Pedrazzoli et al. pro-
pose that high-dose chemotherapy might
be more effective for patients with
breast cancer who respond to conven-
tional treatment. This type of analysis is
erroneous and misleading. Patients with
advanced breast cancer who respond to
conventional therapy have a better prog-
nosis than those who do not (1). This is
true whether they receive high-dose che-
motherapy or not (1,2). However, in the
absence of compelling evidence that
high-dose chemotherapy improves out-
comes in the overall group of patients
with advanced disease, it is inappropri-
ate to conclude that response to conven-
tional therapy selects patients who
will benefit from high-dose chemo-
therapy.
Patients who still demonstrate mul-
tiple, positive axillary lymph nodes after
preoperative chemotherapy have an un-
favorable prognosis (3). In our study,
eligible patients who received preopera-
tive chemotherapy had responded to
preoperative therapy, but they still had
four or more positive axillary lymph
nodes. When this study was designed,
only patients at very high risk of recur-
rence were acceptable candidates for
high-dose chemotherapy, which in the
late 1980s was associated with a sub-
stantial (5%–8%) treatment-related mor-
tality rate.
The results of our study showed no
differences in outcome for the overall
randomly assigned groups and for the
subsets whom we planned to analyze
prospectively. Many additional subset
analyses could be undertaken retrospec-
tively. However, considering the small
sample size and the retrospective and
unplanned nature of additional analyses
(such as a search for prognostic factors),
any results would be tentative at best.
We thought that the presentation of the
overall results, based on the planned
analyses, would best serve our readers.
We discussed the nonmyeloablative
character of the high-dose CEP (cisplat-
in, etoposide, and cyclophosphamide)
therapy on page 231 of our paper. Al-
though Pedrazzoli et al. suggest that
other high-dose regimens might have
greater antitumor efficacy, the evidence
in support of this statement is lacking.
The report of the North American Bone
Marrow Transplant Registry found no
statistically significant differences
among the various preparatory regimens
in use today (4). Furthermore, the sec-
ond reference used by Pedrazzoli et al.
to suggest the superiority of other
“single, more intensive, and possibly
more active regimens” failed to show
any difference between conventional
dose and high-dose chemotherapy (5).
We again conclude that, on the basis
of our small randomized trial, we were
able to rule out a large (>30%) differ-
ence in progression-free and overall sur-
vival rates in patients with high-risk
breast cancer. Definitive conclusions
about the therapeutic worth of high-dose
chemotherapy for primary and/or meta-
static breast cancer await the mature re-
sults of ongoing, large, randomized
clinical trials.
GABRIEL N. HORTOBAGYI
AMAN U. BUZDAR
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